Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Studies from Beckman Research Institute, Division of Virology further understanding of vaccines
August 6th, 2008
Research findings, 'A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector,' are discussed in a new report. "A therapeutic CMV vaccine incorporating an antigenic repertoire capable of eliciting a cellular immune response has yet to be successfully implemented for patients who already have acquired an infection. To address this problem, we have developed a vaccine candidate derived from modified vaccinia Ankara (MVA) that expresses three immunodominant antigens (pp65, IE1, IE2) from CMV," scientists writing in the journal Virology report. "The novelty of this vaccine is the fusion of two adjacent exons from...
Source: Vaccine Weekly (2008-08-06)
|
